ACADIA Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Catherine Owen Adams
Chief executive officer
US$8.3m
Total compensation
| CEO salary percentage | 11.26% |
| CEO tenure | 1.9yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$376m |
| Dec 31 2025 | US$8m | US$930k | US$391m |
| Sep 30 2025 | n/a | n/a | US$261m |
| Jun 30 2025 | n/a | n/a | US$222m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | US$8m | US$246k | US$226m |
Compensation vs Market: Catherine's total compensation ($USD8.26M) is above average for companies of similar size in the MX market ($USD1.32M).
Compensation vs Earnings: Catherine's compensation has been consistent with company performance over the past year.
CEO
Catherine Owen Adams (56 yo)
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. She served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She serves as Ind...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$8.26m | no data | |
| Executive VP & CFO | 4.9yrs | US$3.12m | 0.039% MX$ 31.0m | |
| Executive VP | 2.6yrs | US$2.93m | 0.0044% MX$ 3.6m | |
| Executive VP and Head of Research & Development | 2.3yrs | US$2.89m | 0.011% MX$ 8.9m | |
| Executive VP & Chief Commercial Officer | 1.7yrs | US$857.02k | 0% MX$ 0 | |
| Senior VP | 1yr | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | 2.9yrs | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Finance | no data | no data | 0.0076% MX$ 6.1m | |
| Senior Vice President of Rare Disease Franchise | 1.3yrs | no data | no data | |
| Senior VP | 1yr | no data | no data |
Experienced Management: ACAD *'s management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$8.26m | no data | |
| Independent Director | 18.3yrs | US$395.21k | 0.014% MX$ 10.9m | |
| Independent Director | 10.7yrs | US$385.05k | 0.060% MX$ 48.2m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 10.8yrs | US$399.03k | 0.025% MX$ 20.2m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 10.6yrs | US$393.94k | 0.0071% MX$ 5.7m | |
| Independent Chairman of the Board | 13.6yrs | US$415.54k | 0% MX$ 0 | |
| Independent Director | less than a year | no data | 0.0012% MX$ 938.8k | |
| Independent Director | 3.8yrs | US$400.30k | 0.019% MX$ 15.4m | |
| Independent Director | 5.9yrs | US$392.67k | 0.020% MX$ 15.7m |
Experienced Board: ACAD *'s board of directors are seasoned and experienced ( 10.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/05 05:09 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 38 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Jack Allen | Baird |
| Joel Beatty | Baird |